Researchers from Heidelberg University Hospital and the University of Lucerne as well as international scientists, patient representatives and European cancer societies have pooled scientific data and ...

After an average of 44 months (with a range of 26-62 months), the rate of cancer recurrence in the axillary nodes was 2.9% in the 103 patients who received radiation alone with no further lymph node ...

Clinical relevance of the use of FDG PET/CT in locally advanced breast cancer. This is an ASCO Meeting Abstract from the 2012 Breast Cancer Symposium. This abstract does not include a full text ...

Advances in cancer treatment mean more people are living longer after a cancer diagnosis. But some survivors develop lymphedema—long-term swelling in the arms, hands, legs or feet that can cause pain, ...

Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST ...

Neoadjuvant chemotherapy (NAC) is one of the standard-of-care therapies for breast cancer (BC) with axillary lymph node (ALN) metastases. However, the response to this therapy varies depending on the ...

Targeted axillary dissection (TAD) emerged as the optimal minimally invasive technique, demonstrating superior diagnostic accuracy over other approaches in patients with node-positive breast cancer ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Lymphedema risk is linked to lymph node removal, not breast surgery, with axillary dissection and radiation being key factors. Maintaining full arm mobility, strength, and tissue health is crucial in ...

Please provide your email address to receive an email when new articles are posted on . Patients with early invasive breast cancer who did not receive axillary surgery had noninferior outcomes as ...